Immune changes linked to diabetes could guide development of new cancer treatments

New mouse and human immune-cell research suggests hyperglycemia in type 1 diabetes may slow certain tumors by reprogramming T cells to fight cancer more effectively. The study identifies an IGF1-IGF1R signaling pathway as a potential target for future T cell-based immunotherapies.